{"preliminary_commentary":{"by_channel":{"x_thread":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["lanreotide"]],"indication":"non-resectable duodeno-pancreatic neuroendocrine tumors after first-line treatment","name":"REMINET","nct_id":"NCT02288377","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=reminet-nct02288377. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"REMINET","arms":[{"description":"In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression","label":"lanreotide","type":"EXPERIMENTAL"},{"description":"In this arm, patients will receive placebo every 28 days until disease progression","label":"placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2020-01","type":"ACTUAL"},"conditions":["Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours"],"enrollment":{"count":53,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"lanreotide","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2023-01-18","lead_sponsor":"Federation Francophone de Cancerologie Digestive","official_title":"A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT","overall_status":"TERMINATED","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2020-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Proportion of Patients Alive and Progression-free at 6 Months","timeFrame":"6 months"}],"references":[{"citation":"Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11.","pmid":"28292641","type":"BACKGROUND"},{"citation":"Guiney DG Jr, Hasegawa P, Davis CE. Homology between clindamycin resistance plasmids in Bacteroides. Plasmid. 1984 May;11(3):268-71. doi: 10.1016/0147-619x(84)90035-0.","pmid":"6087395","type":"RESULT"},{"citation":"Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study. Eur J Cancer. 2022 Nov;175:31-40. doi: 10.1016/j.ejca.2022.07.033. Epub 2022 Sep 7.","pmid":"36087395","type":"DERIVED"}],"start_date":{"date":"2015-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)","url":"https://clinicaltrials.gov/study/NCT02288377"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/reminet-nct02288377"}